SCHEMBL18151944

SCHEMBL18151944

O=C1CC2CC[C@@H](C1)N2C(=O)c1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ELOVL6 Q9H5J4 1/20 0.47
L3MBTL3 Q96JM7 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
ACHE P22303 1/20 0.45
ALDH1A1 P00352 3/20 0.44
KDM4E B2RXH2 2/20 0.42
POLB P06746 2/20 0.42
HPGD P15428 1/20 0.42
EPHX1 P07099 1/20 0.41
MCL1 Q07820 1/20 0.41
OPRM1 P35372 1/20 0.41
OPRD1 P41143 1/20 0.41
CHRNA7 P36544 2/20 0.40
CHRNB2 P17787 1/20 0.40
CHRNB4 P30926 1/20 0.40
CHRNA3 P32297 1/20 0.40
CHRNA4 P43681 1/20 0.40
HTR3E A5X5Y0 1/20 0.40
HTR3B O95264 1/20 0.40
HTR3A P46098 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18151912 1.00 ELOVL6 (0.47) ELOVL6L3MBTL3L3MBTL1ACHEALDH1A1
SCHEMBL18151913 0.81 ELOVL6 (0.52) ELOVL6L3MBTL3L3MBTL1ACHEALDH1A1
SCHEMBL2990830 0.80 ELOVL6 (0.48) ELOVL6L3MBTL3L3MBTL1ACHEALDH1A1
SCHEMBL3456856 0.79 ALDH1A1 (0.44) L3MBTL3L3MBTL1ALDH1A1KDM4EPOLB
SCHEMBL14172576 0.79 CHRNB2 (0.56) ELOVL6L3MBTL3L3MBTL1ACHEALDH1A1
SCHEMBL21162194 0.79 ELOVL6 (0.53) ELOVL6L3MBTL3L3MBTL1ACHEALDH1A1
Hydrochloric Acid SCHEMBL27153138 0.77 CHRNB2 (0.54) ELOVL6L3MBTL3L3MBTL1ACHEALDH1A1
SCHEMBL23021253 0.76 L3MBTL1 (0.40) L3MBTL3L3MBTL1ALDH1A1KDM4EPOLB
SCHEMBL5878652 0.75 CHRNA7 (0.50) ALDH1A1KDM4ECHRNA7HTR3A
SCHEMBL984359 0.74 MAPK1 (0.41) POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3283622-B1 MUTANT TRANSAMINASES AS WELL AS METHODS AND USES RELATING THERETO HOFFMANN LA ROCHE (CH) 2019-07-03 EP disclosed
US-10017749-B2 Mutant transaminases as well as methods and uses relating thereto HOFFMAN-LA ROCHE INC. (US) 2018-07-10 US disclosed
EP-3283622-A1 MUTANT TRANSAMINASES AS WELL AS METHODS AND USES RELATING THERETO F. Hoffmann-La Roche AG (CH) 2018-02-21 EP disclosed
WO-2016166120-A1 MUTANT TRANSAMINASES AS WELL AS METHODS AND USES RELATING THERETO F. HOFFMANN-LA ROCHE AG (CH) 2016-10-20 WO disclosed
US-20160304843-A1 MUTANT TRANSAMINASES AS WELL AS METHODS AND USES RELATING THERETO HOFFMANN-LA ROCHE INC. (US) 2016-10-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10017749-B2 Mutant transaminases as well as methods and uses relating thereto GOT1, GOT2, OAT ELOVL6 1741/4885L3MBTL3 1525/4885L3MBTL1 629/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.